LOGIN
Zoledronic acid for postmenopausal osteoporosis reduces fracture risk and improves BMD
January 2014
Zoledronic acid for postmenopausal osteoporosis reduces fracture risk and improves BMD
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis
J Bone Miner Metab. 2011 May;29(3):328-33. doi: 10.1007/s00774-010-0223-y. Epub 2010 Oct 5Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
323 Chinese women were randomized to evaluate the efficacy and safety of a once-yearly zoledronic acid treatment for postmenopausal osteoporosis. Patients received either annual infusions of zoledronic acid or placebo for 3 consecutive years and were assessed at the end of this period. Results revealed that zoledronic acid reduced the risk of vertebral fractures and increased the bone mineral dens...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.